Regional Cancer Therapy

This volume provides a biological and pharmacological background for regional cancer therapy, strategies and techniques for regional therapies, and specific indications and results for different tumor entities. Clinical trial concepts and detailed treatment protocols are also presented. This book is essential reading for researchers and clinicians engaged in seeking advanced therapeutic options for cancer patients worldwide.

Present knowledge in regional cancer therapy is presented in this volume. The latest research addresses the questions of optimal drug development, the best galenic form and schedule to control tissue distribution at the tumor site and efficient treatment of specific anatomical regions.

Microspheres and Regional Cancer Therapy takes an interdisciplinary approach to the subject of microspheres and regional cancer therapy. It synthesizes laboratory and clinical data to demonstrate the utility of microsphere-based strategies in the treatment of localized solid tumors (particularly in the liver) not amenable to surgery and as a component of strategies for treatment of disseminated disease. Using the same techniques that show the deficiencies of delivery strategies involving antibodies, liposomes, and synthetic polymers, clear evidence is presented describing how microspheres of appropriate size can be localized in solid tumor deposits in the liver with little exposure to other organs. To exploit this phenomenon, the extent and nature of the incorporation of active agents within microspheres is discussed in relation to release, pharmacokinetics, and tumor response achieved by intensification of therapy in the manner described. This book will benefit laboratory-based scientists and clinicians in pharmaceutics, pharmacology, physiology, surgical oncology, and nuclear medicine. In addition, cancer clinicians interested in the value of regional therapy will be able to evaluate the underlying theory and learn the necessary methodology.

Charles Hayter chronicles the work of Canadian provinces in establishing the cancer programs that remain the framework for modern systems. Focusing on the compromises these programs required, which anticipated later conflicts over Medicare, Hayter concludes by revealing the historical roots of current problems in cancer care.

This book is a state-of-the-art overview of cancer regional therapy (CRT) for the surgeons and interventional radiologists active in CRT development and research. The goals of this book are 1) to review the theory and practice of cancer regional therapies including pharmacology, devices, techniques, and workflow, 2) illustrate the most common procedures performed in the interventional and operating rooms, and 3) discuss data supporting use of CRT. This is meant to be a definitive text on the theory and practice of CRT. It begins with a summary of the history, technical principles that underlie regional therapy. The following parts discuss current data and practice in peritoneal, liver, limb, pleural and other sites. Included in the practice are considerations of workflow and financial issues revolving around CRT. Novel techniques and therapies under investigation are presented to inform the direction of the field. Cancer Regional Therapy summarizes the history, current technology, common procedures, and future prospects in this field and includes procedures from many surgical and interventional radiologic disciplines.

Journeys in Cancerland offers two object lessons in patient participation. For a long time, patients barely participated in their own care. Once diagnosed with a disease like cancer, they would enter an all-consuming acute care system that took over their lives until they went into remission or died. That this is no longer the case is due, for the most part, to patients and caregivers like John-Peter Bradford and Lisa Newman who have begun to take charge of their care. Their stories are not merely instructive about cancer -- they are lessons in how to live with life threatening illness and how to face death. John-Peter Bradford is CEO of Bradford Bachinski Limited and a member of the Cancer Care Advisory Committee of the Ottawa Regional Cancer Foundation. Lisa Newman has over thirty years' experience in the Ontario healthcare system as a clinician, supervisor, and manager. Foreword by Sholom Glouberman, President of the Patients' Association of Canada